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Abstract
Introduction: Food allergy is an increasing problem with limited therapeutic approaches apart from
to the eviction diet.
Case presentation: A 40-year-old female patient with food allergy symptoms was polysensitized to
almost all vegetable food since the age of 36; the onset of symptoms was during pregnancy. The
allergological study demonstrated positive skin prick tests (SPT) to nuts, legumes, cereals, spices,
several fresh fruits including peach, and other groups of vegetable foods however, it was negative to
common aeroallergens. Serum specific IgE levels were negative (<0.35 kU/L) to profilin and
carbohydrate determinants, but positive to Pru p 3 (3.5 kU/L). Positive double-blind placebo-
controlled food challenge to peach confirmed the allergic disease. She received specific sublingual
immunotherapy with native Pru p 3 at a concentration of 40 mg/ml with 5 administrations per week
and a cumulative dose of 200 mg of nPru p 3 per month. After an ultra-rush build-up phase concluded
in one day she continued therapy during a year with 5 administrations per week. The clinical
evolution and laboratory studies demonstrated an early reduction on SPT reactions with no relevant
changes on serum specific IgE, IgG, IgG1 and IgG4 to Pru p 3 during the immunotherapy period. The
challenge test was negative 4 months after the beginning of the SLIT. Regarding clinical response she
markedly improved after the first month of treatment, and by the 3th month she had no major
vegetable dietary restrictions, except for nuts and pepper.
Conclusion: These results demonstrate the excellent efficacy and safety of sublingual specific
protein immunotherapy developed according to the patient specific sensitivity profile to Pru p3.
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Food allergy is an increasing problem in the western
countries, confirmed by several studies in children and
adult patients [1]. In adult population the prevalence of
food allergy varies among geographical areas, possibly in
relation to local dietary habits and pollen exposures [2]. In
Mediterranean region and Southern Europe fruits from
Rosaceae family, including apple, peach and pear are
frequently linked to clinical allergic reactions [3]. In
addition to the specific allergens identified from each
food other proteins are able to induce sensitization and
specific IgE response [2].
Lipid transfer proteins (LTP) form a broad and widespread
group of proteins, particularly of plant origin [4]. They
represent a class of ubiquitous allergens specific for foods
such as fresh fruits and cereals, and responsible for allergy
reactions favours because of its stable and resistant
structure to harsh physicochemical conditions with several
well-conserved domains which may condition a high
degree of cross-reactivity among botanically unrelated
foods [3,4]. In addition to these proteins commonly
involved in food allergy, profilins from pollens and plant
foods as well as carbohydrate determinants (CCDs) can
induce IgE cross-reactive responses in pollen-allergic
patients [5,6].
In spite of the enormous advances in the knowledge of IgE
food allergy the treatment is still based onthe avoidance of
the offending food. In fact there is not an effective
treatment yet [7]. However, in cases of the most common
food allergens avoidance is difficult to accomplish, and
severe reactions from accidental exposures occur too often
[8]. The first attempts of specific immunotherapy were
performed with peanut extract by subcutaneous route, but
with a high ratio of adverse reactions [9]. Oral and
sublingual desensitization strategies were more recently
tried for milk, egg, peanut and hazelnut allergies [8].
Despite the encouraging results, these therapies were
attempted in patients allergic to a specific group of food
allergens. However many patients suffering from food
allergy are sensitised to panallergens which cross-react
within an extensive group of different foods.
Polysensitization to a wide range of food allergens is
common in some patients, particularly in those reacting to
vegetables. Avoidance is extremely difficult and can induce
severe dietary restrictions with consequent metabolic
imbalance. These patients usually have a higher risk of
increasing severity of symptoms and, potentially enhance
the range of vegetable food sensitizations.
Case presentation
During pregnancy a 36-year-old portuguese caucasian
female patient started recurrent crisis of urticaria/
angioedema, and three months after the delivery she
underwent an allergological study. She referred a wide
range of symptoms 15-20 minutes after ingestion of the
majority of vegetable foods: oral allergy syndrome (OAS),
urticaria/angioedemea, skin flush or rhinoconjuntivitis
requiring high doses of systemic H1 antihistamines, so a
severe dietary restriction was established. The allergologi-
cal evaluation including commercial skin prick tests (SPT,
Bial/Aristegui-Spain), prick-prick with fresh foods, and
serum specific IgE (Phadia-Sweden) demonstrated a
polysensitization to almost all vegetables food (fresh
fruits, nuts, legumes, cereals, spices in others). Interest-
ingly, the intensity of SPT reactivity and the serum specific
IgElevels showed changes alongthetime ofeach 6 months
clinical evaluation. They increased or decreased according
to the specific food intake. The strictly restriction of a
group of foods resulted on a decrease of sensitization to
them however a progressive increasing sensitization was
observed to those other vegetables foods better tolerated
o nt h em o m e n to fs e t t i n gu pt h ed i e ta n da sa
consequences not withdrawn from it. This oscillating
clinical profile during a period of 4 years was implicated
on metabolic disorder (hypertension, hypoalbumin and
hypercholesterol serum levels). At the age of 40 years old
she was submitted to a study that results on a specific
treatment.
1. Allergological study
Skin prick tests confirmed the sensitization to a wide range
of vegetable foods and no sensitization to most common
aeroallergens. Total IgE was 70 UI/mL, and serum specific
IgE levels confirmed the SPT reactivity. Specific IgE against
peachandpeachLTP(rPrup3)were1.5kU/Land3.5kU/L
respectively whereas negative values (<0.35 kU/L) were
obtained for peach profilin (rPru p 4), birch profilin
(rBet v 2) and CCD (Phadia, Upsala, Sweden).
The double-blind placebo-controlled food challenge
(DBPCFC) to peach, according previous description of
Fernández-Rivas et al. [10], was positive at first dose with
OAS and rhinitis, and promptly remitted under conve-
nient parenteral treatment.
Regarding these clinical and laboratory data the patient
underwent an individualized treatment using a specific
allergen which we were strong convinced that was
responsible for the etiopathogenesis of the allergic vegetal
food disease.
2. Methodology
The study was performed with the approval of the hospital
ethics committee, and the written consent of the patient.
All the clinical evaluation and laboratory measurements
were performed at the beginning of the treatment period,
and at 4, 8 and 12 months after the beginning. The
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immunotherapy period and the integrity of the immune
system were evaluated by analysis of blood cell counts,
blood biochemistry, liver enzyme studies, ionogram,
glucemia and renal function.
Peach LTP (nPru p 3) purificaction
Peach peel was homogenated into Björksten [11] buffer
and after centrifugation the supernatant was dialysed
against 20 mM phosphate, pH 6), filtered (0.22 mm) and
applied onto a 5 mL Capto S cationic column using an Akta
prime system. Bound proteins were eluted with 20 mM
phosphate, pH 6; 1 M NaCl, at a flow rate of 5 mL/min.
Further purification was achieved by gel filtration using a
Superdex 75 16/60 column equilibrated with PBS buffer.
nPru p 3 was obtained at the 10 kDa fraction.
SPT
The SPT were performed in duplicate on the volar surface
of the forearm according to standard procedure [12] with
native Pru p 3 at the following concentrations: 1, 10, 100
and 500 mg/ml, with prick lancettes (Stallergenes, Antony,
France) using one sterile lancette for each test. Histamine
phosphate (10 mg/ml) and sterile serum saline (Bial/
Aristegui, Spain) were used as positive and negative
controls, respectively. Wheal areas were marked 15 min-
utes after the puncture with a fine-tipped ball-point pen
and transferred by transparent adhesive tape onto paper
for subsequent evaluation.
Total and specific IgE, IgG, IgG1 and IgG4
Total IgE was determined by the CAP System IgE FEIA
(Phadia, Sweden). Serum specific IgE to nPru p 3 was
measured by means of EAST technique (Enzyme Allergo
Sorbent Test) and IgG against the same allergen by ELISA
method [13].
DBPCFC
As previous referred challenge foods (masked taste) were
prepared immediately before the challenge, and 3 doses
(one eighth, one fourth, and five eighths of total weight of
150 g of fresh peach (peel and pulp) were administered at
1-hour intervals. The test was conducted in the hospital
setting, with careful medical monitoring of the patient,
and full emergency treatment was readily available.
Specific sublingual immunotherapy (SLIT)
The active specific immunotherapy consisted of native Pru
p 3 at only one concentration of 40 mg/ml in NaCl 0.09%,
Phenol 0.5% and 50% glycerol. The patient was instructed
to keep the allergen solution in the mouth for at least
3 minutes and then swallow. The build-up phase was
performed in an ultra-rush schedule and was completed in
one day; it was administered in a one drop step every
30 minutes from 1 drop (2 mg) to 5 drops (10 mg) giving a
cumulative dose of 30 mg of nPru p 3 in the first day. A
maintenance dose of 10 mgp e rd a y( 5d r o p s )a n d
administered 5 times a week was established, obtaining
a cumulative dose of 200 mg of nPru p 3 per month.
The build-up phase and the diary sublingual administra-
tions during the first week of treatment were performed in
a hospital setting with the availability of complete
resuscitation equipment and trained personnel, and the
patient was kept under constant observation after each
administration and for at least 240 minutes after the
last one.
All the rest of the treatment was accomplished by the
patient alone without any kind of special care on the
treatment administration.
Evaluation period of SLIT was from October 2007 to
October 2008, and she was yet under treatment. During
maintenance phase patient attended clinical observation
once every 15 days.
3. Results
SLIT with nPru p 3 was safe and well tolerated because it
did not elicit any adverse reaction. The metabolic
parameters namely cholesterol, albumin and triglycer-
ides returned to normal values. During the build-up
phase the first 3 doses induced oral pruritus and
paresthesias of tongue and lips however, increasing the
doses with no additional pharmacological treatment was
decided. We also emphasize the excellent adaptation of
the patient to treatment, and the full compliance with
the schedule of allergen administration and clinical and
laboratorial tests.
Regarding the allergologic study, a reduction of the mean
diameter in the SPT to nPru p 3 was observed, whereas no
relevant changes on serum specific IgE, IgG, IgG1 and IgG4
to nPru p 3 were detected (Table 1). Besides the excellent
clinical and SPT responses a non-expected maintenance of
nPru p 3 IgE and IgG levels were observed after twelve
months of treatment.
Regarding the clinical efficacy, DBPCFC was positive at the
first dose (18.75 g) before SLIT, inducing SAO and rhinitis,
and it was negative at a cumulative dose of 150 g
(maximum dose, 93.75 g) since the first challenge tests
within the treatment period (4 months). We stress that the
clinical symptoms improved steadily after the first month
of SLIT, and by the3rd month she had nomajor vegetables
dietary restrictions, except for nuts, fruits and pepper. The
antihistamines consumption markedly reduced. She was
advised to avoid any nuts and pepper. Nevertheless when
accidental intake occurred she only reported slight SAO
symptoms, the majority with no need for medication.
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This case report describes a patient with clinical sensitiza-
tion to a wide range of vegetables food with tremendous
consequences on the diet and metabolic imbalance, and
not efficiently controlled with high doses of
antihistamines.
The severity of the allergic symptomatology increases since
the first symptoms appeared so our goal was to develop a
specific immunotherapy for this case. Specific immu-
notherapy to foods have been tried using protein extracts
obtained from the culprit raw sources [7]. We decided to
design an immunotherapy treatment with the purified
cross reactive allergen present in all the allergenic
vegetables food.
SPT reactivity to various concentrations of nPru p 3 was
carried out to look for the suitable immunotherapy
allergen concentration. 10 mg/ml of nPru p 3 was the
allergen concentration needed to induce a mean wheal
similar in size to the one induced by histamine at 10 mg/
ml. Taking this results into account and the manufacturer
previous experience, a concentration of 40 mg/ml of Pru p
3 was chosen as the immunotherapy concentration [14].
This is a high dose of SLIT as the monthly cumulative
maintenance dose is 5 ml at 40 mg/m (200 mg), compared
to the conventional subcutaneous immunotherapy (SIT)
in which the monthly dose is 1 ml at 10 mg/ml (10 mg)
[15]. So it implies a cumulative dose 20 times higher for
SLIT than to SIT.
The use of an ultra-rush schedule probably reduced the
risk of side effects and explains the excellent tolerance both
in the build-up and maintenance phases. The minor local
symptoms occurring on the first 3 doses were not so
serious to require administration of relive medication or
the interruption of the treatment.
This clinical case confirmed that this treatment is safe, at
least at a concentration that we used, was well tolerated
and extremely effective on clinical symptoms. A tolerance
to the intake of the majority of vegetable food sources was
reached, the DBPCFC were promptly negative, and an
improvement of the metabolic imbalance was obtained.
At the moment, only nuts and particularly pepper induce
SAO symptoms. It is still unknown if pepper has large
amounts of LTP, besides the ability to induce specific IgE
mechanism [1]. The decreasing SPT results to Pru p 3 are in
agreement with the clinical response. However the specific
IgE and IgG levels did not show significant differences as
expected. The patient is still under treatment and we
believe that more pronounced immunological changes
will be observed in future.
Patient’s perspective
I real fell well with this treatment and my life really
improved, because I have no limitations on my diet and
my health markedly improved since doctors started this
knew treatment for my allergic disease.
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th month of active treatment.
T = 0 T = 4 months T = 8 months T = 12 months
SPT (mm)
Histamine 6 6 7 8
nPru p 3 1 µg/ml 3 3 2 2
nPru p 3 10 µg/ml 6 4 3 2
nPru p 3 100 µg/ml 12 5 4 3
nPru p 3 500 µg/ml 14 6 5 4
sIg levels
sIgE Pru p 3 (kU/L) 1.8 1.7 1.2 1.9
sIgG Pru p 3* 0.76 0.94 0.84 0.76
sIgG1 Pru p 3** 0.60 0.74 0.71 0.62
sIgG4 Pru p 3** 0.83 1.01 1.04 0.75
DBPCFC Positive Negative Negative Negative
*Absorbance at 492 nm with 1:200 diluted serum
**Absorbance at 492 nm with 1:50 diluted serum
***Absorbance at 492 nm with 1:100 diluted serum
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